We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. The company manufactures a range of specialty products that include various pharmaceutical dosage forms. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and medicated and herbal lozenges. The company was incorporated in 1976 and is headquartered in Mumbai, India.
TODAY'S HIGH
1588.35
TODAY'S LOW
1560
52 WEEK HIGH
1985
52 WEEK LOW
1370
% of Shares Held by
All Insider
54.36%
% of Shares Held by
Institutions
22.95%
% of Float Held by
Institutions
50.28%
Number of Institutions
Holding Shares
68
MARKET CAP
12211.90 Cr.
ETERPRISE VALUE
11764.05 Cr.
NO. OF SHARES
7.72 Cr.
BOOK VALUE
256.163
DIV. YIELD
8.5%
DEBT
55.46 Cr.
GROSS PROFIT
1319.80 Cr.
CASH
767.30 Cr.
REVENUE
2328.11 Cr.
REVENUE/SHARE
301.256
Particulars | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
---|---|---|---|---|
Investments | -224.06 Cr. | 91.25 Cr. | 10.37 Cr. | 6 Cr. |
Change To Liabilities | 46.47 Cr. | 52.10 Cr. | -28.57 Cr. | 19.36 Cr. |
Total cashflows from Investing Activities | -230.67 Cr. | 23.92 Cr. | -27.66 Cr. | -20.68 Cr. |
Net Borrowings | -7.83 Cr. | -2.36 Cr. | -5 Lakhs | 3.95 Cr. |
Total Cash from Financing Activities | -87.42 Cr. | -306.05 Cr. | -155.73 Cr. | -59.52 Cr. |
Other Liabilities | 0 | 0 | 21 Cr. | 21 Cr. |
Total Assets | 0 | 0 | 0 | 0 |
Net Income | 447.96 Cr. | 272.04 Cr. | 193.46 Cr. | 138.34 Cr. |
Change in Cash | -3.27 Cr. | -6.38 Cr. | 10.89 Cr. | 42.71 Cr. |
Effect of Exchange Rate | 3.55 Lakhs | -1.29 Lakhs | -2.31 Lakhs | -2.31 Lakhs |
Total Cash from Operating Activities | 314.78 Cr. | 275.74 Cr. | 194.32 Cr. | 122.92 Cr. |
Depreciation | 68.32 Cr. | 65.99 Cr. | 54.87 Cr. | 56.05 Cr. |
Other Cashflows from Investing Activities | 1.27 Cr. | 3.17 Cr. | 3.75 Cr. | 1.88 Cr. |
Dividends Paid | -73.24 Cr. | -141 Cr. | -20.79 Cr. | -10.33 Cr. |
Change to Inventory | -70.08 Cr. | -30.91 Cr. | -30.02 Cr. | -13.56 Cr. |
Change to Account Receivables | -70.59 Cr. | -11.49 Cr. | -13.87 Cr. | -52.87 Cr. |
Other Cashflows from Financing Activities | -6.34 Cr. | -1.86 Cr. | -3.86 Cr. | -3.13 Cr. |
Change to Net Income | -107.63 Cr. | -72.32 Cr. | -3.31 Cr. | -25.31 Cr. |
Capital Expenditures | -47.77 Cr. | -72.96 Cr. | -49.12 Cr. | -36.42 Cr. |
Particulars | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
---|---|---|---|---|
Research Development | None | None | None | None |
Effect of Accounting Charges | None | None | None | None |
Income Before Tax | 596.88 Cr. | 348.89 Cr. | 286.99 Cr. | 193.95 Cr. |
Minority Interest | 3.70 Cr. | 2.50 Cr. | 2.80 Cr. | 2.77 Cr. |
Net Income | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. | 164.97 Cr. |
Selling General Administrative | 425.77 Cr. | 406.83 Cr. | 382.03 Cr. | 321.24 Cr. |
Gross Profit | 1319.80 Cr. | 1122.22 Cr. | 1023.93 Cr. | 856.08 Cr. |
Ebit | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. | 164.97 Cr. |
Operating Income | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. | 164.97 Cr. |
Other Operating Expenses | 338.05 Cr. | 330.84 Cr. | 328.13 Cr. | 313.03 Cr. |
Interest Expense | -6.74 Cr. | -2.91 Cr. | -3.41 Cr. | -2.32 Cr. |
Extraordinary Items | None | None | None | None |
Non Recurring | None | None | None | None |
Other Items | None | None | None | None |
Income Tax Expense | 148.36 Cr. | 76.50 Cr. | 93.02 Cr. | 55.23 Cr. |
Total Revenue | 2042.52 Cr. | 1774.72 Cr. | 1643.20 Cr. | 1408.38 Cr. |
Total Operating Expenses | 1555.21 Cr. | 1456.51 Cr. | 1384.94 Cr. | 1243.40 Cr. |
Cost of Revenue | 722.71 Cr. | 652.50 Cr. | 619.26 Cr. | 552.30 Cr. |
Total Other Income Expense Net | 109.57 Cr. | 30.67 Cr. | 28.73 Cr. | 28.97 Cr. |
Discontinued Operations | None | None | None | None |
Net Income from Continuous Ops. | 448.52 Cr. | 272.39 Cr. | 193.96 Cr. | 138.71 Cr. |
Net Income Applicable to Common Shares | 447.96 Cr. | 272.04 Cr. | 193.46 Cr. | 138.34 Cr. |
Particulars | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
---|---|---|---|---|
Intangible Assets | 32.10 Cr. | 30.09 Cr. | 23.37 Cr. | 22.65 Cr. |
Capital Surplus | 50.76 Cr. | 50.76 Cr. | 50.76 Cr. | 50.76 Cr. |
Total Liabilities | 424.68 Cr. | 382.57 Cr. | 309.02 Cr. | 320.77 Cr. |
Stock Holder Equity | 1809.72 Cr. | 1435.48 Cr. | 1480.12 Cr. | 1441.55 Cr. |
Minority Interest | 3.70 Cr. | 2.50 Cr. | 2.80 Cr. | 2.77 Cr. |
Other Liabilities | 102.68 Cr. | 103.72 Cr. | 97.03 Cr. | 119.90 Cr. |
Total Assets | 2238.11 Cr. | 1820.56 Cr. | 1791.94 Cr. | 1765.10 Cr. |
Common Stock | 15.45 Cr. | 15.45 Cr. | 16.04 Cr. | 16.71 Cr. |
Retained Earnings | 1735.41 Cr. | 1373.37 Cr. | 1413.87 Cr. | 1371.58 Cr. |
Other Liabilities | 74.27 Cr. | 68.07 Cr. | 64.83 Cr. | 45.65 Cr. |
Good Will | 57.45 Cr. | 53.14 Cr. | 53.14 Cr. | 53.14 Cr. |
Treasury Stock | 8.08 Cr. | -4.10 Cr. | -56.98 Lakhs | 2.48 Cr. |
Other Assets | 13.38 Cr. | 10.52 Cr. | 8.89 Cr. | 11.02 Cr. |
Cash | 28.68 Cr. | 29 Cr. | 35.39 Cr. | 27.94 Cr. |
Current Liabilities | 345.27 Cr. | 313.26 Cr. | 244.18 Cr. | 275.11 Cr. |
Long Term Asset Charges | 6.94 Cr. | 6.57 Cr. | 0 | 0 |
Short Long Term Debt | 0 | 0 | 0 | 0 |
Other Stockholder Equity | 8.08 Cr. | -4.10 Cr. | -56.98 Lakhs | 2.48 Cr. |
Property Plant Equipment | 569.65 Cr. | 584.19 Cr. | 559.50 Cr. | 581.11 Cr. |
Total Cur. Assets | 1552.60 Cr. | 1073.15 Cr. | 1051.15 Cr. | 1047.21 Cr. |
Long Term Investments | 12.90 Cr. | 69.45 Cr. | 95.87 Cr. | 49.95 Cr. |
Net Tangible Assets | 1720.16 Cr. | 1352.25 Cr. | 1403.60 Cr. | 1365.76 Cr. |
Short Term Investments | 0 | 0 | 2.99 Cr. | 84.43 Lakhs |
Net Receivables | 399.24 Cr. | 361.35 Cr. | 324.83 Cr. | 307.32 Cr. |
Long Term Debt | 0 | 0 | 0 | 0 |
Inventory | 347.44 Cr. | 274.66 Cr. | 243.75 Cr. | 213.73 Cr. |
Accounts Payable | 186.92 Cr. | 167.96 Cr. | 117.37 Cr. | 110.39 Cr. |